Locations:
Search IconSearch
February 19, 2019/Geriatrics

PET Ligand GE-180 Cleared for Testing to Assess Inflammation in Neurodegenerative Disease

Cleveland Clinic IND application is first approved in Parkinson’s and Alzheimer’s

19-NEU-122_CQD_650x450_hero

Cleveland Clinic Lou Ruvo Center for Brain Health has received FDA approval of its Investigational New Drug (IND) application to test the GE-180 ligand tracer in the brains of individuals with Parkinson’s disease and Alzheimer’s disease.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

The novel tracer will be used in a PET imaging investigation to assess neuroinflammation in the brains of 70 study participants with normal cognitive function or either Parkinson’s or Alzheimer’s disease, with the aim of elucidating links between inflammation and neurodegeneration. The IND makes the Lou Ruvo Center for Brain Health the first trial site testing GE-180 in these patient populations.

While researchers increasingly report findings suggestive of an important role for neuroinflammation in the pathology of neurodegenerative conditions, more research is warranted, particularly in the living brain. Ligand tracers such as GE-180 are used to help better depict protein interactions in living cells.

“We know there is some connection between inflammation and neurodegenerative disease, but we have yet to confirm what it is,” explains principal investigator Aaron Ritter, MD, Director of the Clinical Trials Program at the Lou Ruvo Center for Brain Health, who holds the IND for the GE-180 study. “Until now, it has been hard to quantify in a living brain. The GE-180 tracer is an exciting opportunity to contribute to the science of brain disease in ways that have not previously been studied.”

He adds: “If we can confirm that inflammation plays a role in dementia, this could lead to new treatments that specifically target cognitive decline.”

The two-year imaging investigation is an observational substudy of the Lou Ruvo Center for Brain Health’s Center of Biomedical Research of Excellence (COBRE) grant, which aims to understand the similarities between Parkinson’s and Alzheimer’s diseases. The COBRE grant is funded by Institutional Development Award (IDeA) P20GM109025 from the National Institutes of Health.

Advertisement

Image credit: U.S. National Institute on Aging

Advertisement

Related Articles

Medication Vial
October 14, 2024/Geriatrics/Research
Case Study: Semaglutide Use in Older Patient with Severe Dementia

Complications highlight need to exercise caution when managing geriatric patients

Plate of French fries
Case Study: Candid Discussions Illuminate Value of Simple Pleasures in Elderly Woman With Severe Dementia

Patient’s favorite food helps guide decisions regarding end-of-life interventions

Ambulance
Expanding ED Services to Meet the Needs of An Aging Rural Population

Community hospitals trial geriatric-friendly care model

Grandparent with grandchild
Novel Care Model May Improve Outcomes for Older Adults With Multiple Chronic Conditions

Focus on patients’ priorities can aid decision-making, reduce treatment burden

Elderly man with dementia
Collaborative Project Expands Prognostic Tools for Hospitalized Older Adults With Dementia

Researchers use patient data to strengthen clinical prediction models

23-GER-4067514-CQD-Hero-650×450-1
October 11, 2023/Geriatrics/Research
Electronic Medical Records May Be Key to Diagnosing Delirium in Geriatric Emergency Patients

Structured data helps identify older adults at risk for poor outcomes, defines patients who require more comprehensive assessments

Ad